SLN News & Events

Silence Therapeutics announced that Craig Tooman, who has served as the company's president, CEO and board member since 2022, agreed by mutual consent to end his employment with the company effective December 14. Iain Ross, chairman of the Silence Board, will lead the company with immediate effect on an interim basis. Additionally, James Ede Golightly, a former Silence non-executive director, has been re-appointed to the company's board of directors. An additional appointment of an US-based board member is anticipated in due course.

Reports Q3 revenue $159,000, consensus $3.28M. "Silence continues to focus on operational execution, highlighted by the rapid achievement of full enrollment in our ongoing SANRECO Phase 2 study of divesiran, our first-in-class siRNA for PV," said Craig Tooman, President and Chief Executive Officer at Silence. "We believe the positive momentum in our divesiran PV program, combined with exciting advancements in our early-stage pipeline, positions us well for both near and long-term value creation. We are looking forward to a strong finish to the year and meaningful pipeline catalysts ahead in 2026."

Silence Therapeutics announced it has completed patient enrollment in the SANRECO Phase 2 study of divesiran, a first-in-class siRNA targeting TMPRSS6, for the treatment of polycythemia vera. Initial topline results from the SANRECO Phase 2 study are anticipated in the third quarter of 2026.

Reports Q2 revenue $224,000, consensus $3.38M. "The updated data we presented at EHA this past quarter were highly encouraging and supportive of the therapeutic potential of divesiran as a first-in-class siRNA in PV," said Craig Tooman, President and Chief Executive Officer at Silence. "The SANRECO Phase 2 trial of divesiran in PV patients continues to progress towards full enrollment this year and remains our top priority."